Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Enveric Biosciences Inc. - news published 259 - readings 4.482

BACK

Enveric Biosciences Inc.

Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”

Press Releases Enveric Biosciences to Participate in Biotech Showcase 2024 During "J.P. Morgan Week 2024" By wpengine December 20, 2023 No Comments CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the tr ...

20.12.2023

Enveric Biosciences Inc.

Supplemental Prospectus - Form 424B4

PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-275380 1,279,880 Shares of Common Stock Enveric Biosciences, Inc. This prospectus relates to the offer and resale of up to 1,279,880 shares of our common stock, par value $0.01 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares ...

06.12.2023

Enveric Biosciences Inc.

Notice of Effectiveness - Form EFFECT

Notice of Effectiveness UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Notice of Effectiveness Effectiveness Date: December 5, 2023 4:30 P.M. Form: S-1 CIK: 0000890821 Company Name: Enveric Biosciences, Inc. File Number: 333-275380 Attachments Original Link Original Document Permalink Disclaimer Enveric Biosciences Inc. published this content on 05 Dec ...

06.12.2023

Enveric Biosciences Inc.

Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds - Form 8-K

Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds Three novel neuroplastic compounds identified with plans to advance one into expedited preclinical development in 2024 CAMBRIDGE, Mass., December 5, 2023 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric& ...

05.12.2023

Enveric Biosciences Inc.

Amendment to Initial Registration Statement - Form S-1/A

As filed with the Securities and Exchange Commission on December 1, 2023 Registration No. 333-275380 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 95-4484725 (State or other ...

01.12.2023

Enveric Biosciences Inc.

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives - Form 8-K

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives Expands intellectual property portfolio with composition of matter and methods of use claims governing Enveric's EVM301 Series of drug candidates CAMBRIDGE, Mass., November 29, 2023 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company&quo ...

29.11.2023

Enveric Biosciences Inc.

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Press Releases Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry By wpengine November 27, 2023 No Comments Peer-reviewed article describes the creation of a library of novel prodrug derivatives of psilocin from which EB-373 was selected CAMBRIDGE, Mass. - Enve ...

27.11.2023

Enveric Biosciences Inc.

Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)

Press Releases Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023) By wpengine November 24, 2023 No Comments CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeut ...

24.11.2023

Enveric Biosciences Inc.

Failure to Satisfy Listing Rule - Form 8-K

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 21, 2023, Enveric Biosciences, Inc. (the "Company") received a deficiency letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that it is not in complianc ...

22.11.2023

Enveric Biosciences Inc.

Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results - Form 8-K

Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results EVM-301 Series ● Presented and published leading scientific research describing development and screening methods for non-hallucinogenic, neuroplastogenic drug candidates in Enveric's EVM301 Series of candidates targeting the treatment of mental health disorders ● Announced AI-powered drug candi ...

13.11.2023

Enveric Biosciences Inc.

Quarterly Report for Quarter Ending September 30, 2023 (Form 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___ to ___ Commission File ...

13.11.2023

Enveric Biosciences Inc.

Initial Registration Statement - Form S-1

As filed with the Securities and Exchange Commission on November 7, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 95-4484725 (State or other jurisdiction of incorpora ...

08.11.2023

Enveric Biosciences Inc.

Material Agreement - Form 8-K

Item 1.01. Entry Into a Material Definitive Agreement. On November 3, 2023, Enveric Biosciences, Inc. (the "Company") entered into a purchase agreement (the "Purchase Agreement") and a registration rights agreement (the "Registration Rights Agreement"), with Lincoln Park Capital Fund, LLC ("Lincoln Park"), pursuant to which Lincoln Park ...

06.11.2023

Enveric Biosciences Inc.

Submission of Matters to a Vote of Security Holders - Form 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 2, 2023, the stockholders of Enveric Biosciences, Inc. (the "Company") approved certain amendments to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Amended Incenti ...

02.11.2023

Enveric Biosciences Inc.

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin - Form 8-K

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin Expands its intellectual property portfolio with composition of matter claims governing lead clinical candidate, EB-373, a psilocin prodrug being developed for the treatment of depression and anxiety disorders. CAMBRI ...

31.10.2023

Enveric Biosciences Inc. - news published 259 - readings 4.482

Enveric Biosciences Inc.

Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”

Enveric Biosciences Inc.

Supplemental Prospectus - Form 424B4

Enveric Biosciences Inc.

Notice of Effectiveness - Form EFFECT

Enveric Biosciences Inc.

Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds - Form 8-K

Enveric Biosciences Inc.

Amendment to Initial Registration Statement - Form S-1/A

Enveric Biosciences Inc.

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives - Form 8-K

Enveric Biosciences Inc.

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Inc.

Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)

Enveric Biosciences Inc.

Failure to Satisfy Listing Rule - Form 8-K

Enveric Biosciences Inc.

Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results - Form 8-K

Enveric Biosciences Inc.

Quarterly Report for Quarter Ending September 30, 2023 (Form 10-Q)

Enveric Biosciences Inc.

Initial Registration Statement - Form S-1

Enveric Biosciences Inc.

Material Agreement - Form 8-K

Enveric Biosciences Inc.

Submission of Matters to a Vote of Security Holders - Form 8-K

Enveric Biosciences Inc.

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin - Form 8-K

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member